Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results
August 03, 2023 16:01 ET
|
Vaxart, Inc.
On track to report topline data from Phase 2 GI.1 norovirus vaccine challenge study in Q3 2023 Cash runway extended into Q3 2024 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.,...
Vaxart to Host Second Quarter 2023 Business Update and Financial Results Conference Call on August 3
July 27, 2023 08:00 ET
|
Vaxart, Inc.
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report...
Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate
July 06, 2023 08:00 ET
|
Vaxart, Inc.
Met all primary endpoints: Vaccine was well-tolerated with robust immunogenicity Continue to expect topline data from Phase 2 GI.1 challenge study in Q3 2023 SOUTH SAN FRANCISCO, Calif., July 06,...
Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement
June 26, 2023 16:45 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today held its Annual Meeting of Shareholders in a virtual-only format. Preliminary results from the Annual...
Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET
June 21, 2023 16:30 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today encourages its stockholders of record on April 28, 2023, to vote on its proxy if they have not yet...
Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock
June 07, 2023 09:16 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the pricing of its underwritten public offering of 16,000,000 shares of its common stock,...
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
June 06, 2023 16:01 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has commenced an underwritten public offering of its common stock. In addition,...
Vaxart Announces Last Subject Dosed in Phase 2 Trial of its Bivalent Norovirus Candidate, and All Subjects Challenged in Phase 2 Challenge Study of Monovalent Norovirus Candidate
June 06, 2023 08:00 ET
|
Vaxart, Inc.
No Vaccine Related Serious Adverse Events (SAEs) reported to date On track to report topline data from two Phase 2 norovirus vaccine studies over the next 3 months SOUTH SAN FRANCISCO, Calif., June ...
Vaxart Launches New Investor Communication Program, First Event Scheduled for June 15 at 11 a.m. ET
May 31, 2023 08:00 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it is launching an investor communication program that will give investors the ability to...
Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results
May 04, 2023 16:01 ET
|
Vaxart, Inc.
On track to report key top line data from two Phase 2 norovirus vaccine studies mid-year and in Q3 2023 Continue to anticipate cash runway into Q2 2024 Conference call today at 4:30 p.m. ET SOUTH...